Pre-clinical Results with ALN-F12

Pre-clinical Results with ALN-F12

We presented pre-clinical data with ALN-F12 at the International Society of Thrombosis and Haemostasis (ISTH) Congress, held July 8 – 13, 2017 in Berlin, Germany. Data showed that reduction of hepatic factor XII (FXII) expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk. We believe that reduction of plasma FXII by ALN-F12 represents a promising approach for the prophylactic treatment of thrombosis.

View the presentation



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.